Review Article

Obesity and African Americans: Physiologic and Behavioral Pathways

Preetha Anna Abraham, Josh Ben Kazman, Stacey Anne Zeno, and Patricia Anne Deuster

Department of Military and Emergency Medicine (MEM), Uniformed Services University of Health Sciences (USUHS), Room 26, Building 53, 4301 Jones Bridge Road, Bethesda, MD 20814, USA

Correspondence should be addressed to Preetha Anna Abraham; preetha.abraham@usuhs.edu

Received 13 December 2012; Accepted 31 December 2012

Academic Editors: S. A. Acra and M. Furuhashi

Copyright © 2013 Preetha Anna Abraham et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Although progress has been made to understand the association between physiological and lifestyle behaviors with regard to obesity, ethnic differences in markers of obesity and pathways towards obesity remain somewhat unexplained. However, obesity remains a serious growing concern. This paper highlights ethnic differences in African Americans and Caucasians that may contribute to the higher prevalence of obesity among African Americans. Understanding ethnic differences in metabolic syndrome criteria, functioning of the hypothalamic pituitary adrenal axis, variations in glucocorticoid sensitivity and insulin resistance, and physical activity and cardiovascular fitness levels may help to inform practical clinical and public health interventions and reduce obesity disparities.

1. Introduction

Overweight and obesity are chronic health illnesses affecting many children and adults in the United States [1, 2]. The health consequences of overweight and obesity are enormous, particularly the risk of developing chronic diseases such as hypertension, Type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD). Obesity disproportionately affects ethnic minorities, women and individuals from lower socioeconomic groups [3, 4]. In particular, African Americans (AAs) are disproportionately affected by obesity, diabetes, hypertension, and cardiovascular disease, and it is likely that a host of factors interact in complex, and yet unexplained, ways to contribute to these health disparities. The prevalence of overweight or obesity in African women (66%) is 1.4 times that in Caucasian (CA) women (47%) [5], and African American (AA) women may be at greatest risk for the health consequences of obesity and have an almost twofold greater risk of developing diabetes and experiencing hypertension at earlier ages; they also have significantly greater abdominal fat [6] than CA women.

The objective of the present paper is to highlight selected ethnic differences associated with obesity by focusing on factors that contribute to obesity: metabolic Syndrome (MS) indicators, regulation of the hypothalamic pituitary adrenal (HPA) axis, glucocorticoid sensitivity (GS), insulin resistance (IR), and physical activity among AAs and Caucasians (CAs).

2. Metabolic Syndrome

Metabolic Syndrome (MS) is a constellation of factors used globally for identifying individuals at greatest risk for developing CVD and T2DM [7]. This cluster of interrelated risk factors for CVD and T2DM [8, 9] include glucose intolerance (T2DM, impaired glucose tolerance, impaired fasting glycaemia, or insulin resistance/IR), elevated blood pressure, high triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) levels, and excessive waist circumference (central adiposity) [8, 10]. For use as a global tool various organizations formulated simple criteria for MS diagnosis as described by Grundy et al. [11]. The National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) definition of the MS is the one most often used in the United States (USA) [12]. Table 1 shows how to confirm MS by two separate definitions: the NCEP-ATP-III and the International Diabetes Federation (IDF) on the basis of a nondiabetic population [13]. However, despite
the widespread use, the effectiveness of MS criteria in early detection or prediction of disease risk across ethnic groups is very much debated [14–17].

MS is on the rise in USA and more prevalent among Mexican Americans compared with non-Hispanic whites and blacks and among non-Hispanic white men than non-Hispanic black men [19]. The available literature strongly indicates that the criteria for MS should be modified according to racial/ethnic differences [14, 20]. For example, despite a higher prevalence and mortality from CVD, hypertension, and other related chronic diseases, AA women typically have comparable, if not lower, rates of MS than CAs [14]—but this is only because of the current screening criteria.

The blood pressure criterion is suitable for AA and CA as AA have high rates of hypertension and is usually higher than CAs [21–23]. Although this criterion may be biased for AA, no changes in cutoffs for the criteria are needed. Furthermore, fasting glucose levels appear comparable between AAs and CAs [24], indicating that glucose is not a biased criterion. However, one striking and clinically important racial difference across MS criteria relates to dyslipidemia. A large number of studies suggest that AAs, both with and without MS, have much lower rates of dyslipidemia than CAs; that is, AAs usually have significantly lower triglyceride (TG) levels and higher high-density lipoprotein (HDL-C) levels than CAs [14–17]. Table 2 shows the anthropometric and metabolic information of AA and CA participants in one study, whereas fasting morning blood glucose, HOMA-IR (Homeostasis Model Assessment: fasting glucose (mmol/L) \times fasting Insulin (mU/L)/22.5), and blood pressure did not vary by ethnicity; HDL-C was significantly higher and TG was significantly lower in AAs compared to CAs [15]. Thus, two of only five/six criteria for MS are biased such that MS might not be diagnosed in AA.

Yu et al. [25] reported that the activity of lipoprotein lipase (LPL), the enzyme that clears TG-rich lipid particles from the blood, was significantly higher in AAs than CAs. They postulated that this higher LPL activity might minimize the release of free fatty acids (FFA) from peripheral adipose tissue into the circulation to result in normal TG in the presence of IR [25]. Currently, genome-wide association studies (GWASs) are being conducted to elucidate gene-gene and protein-protein interactions and how such interactions might affect levels of TG, HDL, LDL, and other lipid classes [26]. Until then, this does not change the need to develop ethnic-specific criteria.

Another criterion for MS is waist circumference (WC), which serves as a surrogate marker for abdominal obesity [27]. Abdominal obesity is likely a stronger CVD risk factor than the more commonly used measure of BMI [28]. However, studies using advanced techniques to quantify abdominal fat suggest that waist size is not an appropriate marker of abdominal obesity for AA [29, 30]. Overall body composition appears to differ between AA and CA [31], in addition to WC. The debate on whether WC cutoffs should be based on the relationship between WC and BMI or

### Table 1: Two definitions of metabolic syndrome.

| Criteria                  | ATP III (2004)                                                                 | IDF (2005)                                                                 |
|---------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Special instructions      | Any 3 of the following 5 features:                                            | Meet waist circumference criteria + any two of the criteria below WC         |
| Waist circumference       | Male WC ≥ 102 cm                                                             | * Male WC ≥ 94 cm                                                            |
|                           | Female WC ≥ 88 cm                                                            | Female WC ≥ 80 cm                                                            |
| Blood pressure            | ≥130 and/or ≥85 mm Hg or on hypertension medications                         | ≥130 and/or ≥85 mm Hg or on hypertension medications                         |
| Glucose                   | >5.6 mmol/L (includes diabetes)                                              | >5.6 mmol/L (includes diabetes)                                              |
| Lipids                    | TG > 1.7 mmol/L                                                              | TG ≥ 1.7 mmol/L or on TG Rx                                                   |
|                           | HDL-C < 1.036 mmol/L for men or <1.295 mmol/L for women                      | HDL-C <1.036 mmol/L for men or <1.295 mmol/L for women                      |

*Waist circumference (WC) based on European (Caucasian) measurements.

ATP III: adult treatment panel III; IDF: international diabetes federation; WC: waist circumference; TG: triglyceride; HDL-C: high-density lipoprotein; Rx: prescription.

From [13].

### Table 2: Participant characteristics by ethnicity (mean ± SD).

|                      | Caucasians (n = 50) | African Americans (n = 99) |
|----------------------|---------------------|---------------------------|
| **Anthropometrics**  |                     |                           |
| Height (cm)          | 173.3 ± 10.4        | 170.1 ± 10.2              |
| Weight (kg)          | 83.3 ± 19.4         | 80.4 ± 16.8               |
| Body mass index (kg/m²) | 27.5 ± 0.52         | 27.6 ± 0.45              |
| Waist circumference (cm) | 88.1 ± 15.4       | 87.7 ± 12.0               |
| Percent body fat     | 30.5 ± 09.6         | 31.9 ± 08.2               |
| **Metabolic characteristics** |             |                           |
| Fasting glucose (mmol/L) | 5.3 ± 00.7          | 5.1 ± 00.7                |
| Fasting insulin (µU/mL) | 10.2 ± 07.5        | 12.4 ± 07.8               |
| HOMA-IR              | 2.4 ± 01.9          | 2.9 ± 02.0                |
| Systolic BP (mm Hg)  | 123 ± 11.4          | 124 ± 13.0                |
| Diastolic BP (mm Hg) | 68 ± 08.6           | 69 ± 09.1                 |
| Triglycerides (mmol/L) | 1.19 ± 55.2        | 0.77 ± 0.49               |
| HDL-C (mmol/L)       | 1.10 ± 02.9         | 1.21 ± 03.2               |

Homeostasis model assessment of insulin resistance (HOMA-IR); blood pressure (BP); high-density lipoprotein cholesterol (HDL-C).

Note: Ethnic differences significant at *P < 0.05; **P < 0.001.
WC and visceral adipose tissue (WC-VAT) presents another challenge [32]. In particular, AAs have comparable or slightly higher WC than CAs [33, 34]. However, WC does appear to be a superior predictor of mortality risk, regardless of ethnicity [35]. Several studies [24, 36–38] have shown that WC is highly correlated with other components of MS (serum insulin, IR, TG, HDL-C, and systolic and diastolic blood pressure), although differences among racial/ethnic groups were noted. Overall, ethnic-/race-specific cutoffs for WC may be necessary for adequately assessing health risk within different ethnic/race groups.

Currently, C-reactive protein (CRP), a marker of systemic inflammation, is not included in any current definition of MS. However, CRP is independently associated with the risk of myocardial infarction and cardiovascular death [39, 40]. Non-Hispanic African adolescents with MS have higher levels of high-sensitivity CRP than CA adolescents [41]. Ethnic differences in CRP have also been noted, with AA having higher median CRP levels than CA [42]. Due to its predictive value for CVD and T2DM, CRP should be considered as a criterion of MS. Overall, if MS is to function as a valid, early screener for cardiovascular disease, clearly ethnic-specific criteria are needed.

3. Hypothalamic Pituitary Adrenal Axis

The hypothalamic pituitary adrenal (HPA) axis and the locus ceruleus norepinephrine (LC-NE) system represent the primary components of the stress-responsive neuroendocrine systems, and together they manage physiological adaptations to stress to maintain homeostasis [43–45]. Obesity, and abdominal obesity in particular, has been associated with several interesting HPA axis disturbances: (1) hypersecretion of cortisol and/or ACTH in response to various stimuli; (2) heightened glucocorticoid sensitivity; and (3) increased glucocorticoid resistance to negative feedback. These particular pathways influence many systemic processes relevant to health, including metabolic, cardiovascular, and blood pressure regulation, as well as immune and inflammatory function.

Studies on the HPA axis and obesity are complicated and controversial. Some studies report comparable basal cortisol levels in obese relative to normal weight individuals [46], yet others report elevated basal cortisol levels in obese individuals [47]. Additionally, evidence suggests that diurnal rhythms of cortisol are abnormal in obese individuals, with higher afternoon/evening levels and lower than normal upon a wakening, to result in a flatter slope [48]. Interestingly, overweight AAs have been reported to have significantly lower awakening cortisol levels than overweight CAs despite having similar BMI [49], and disrupted diurnal cortisol rhythms were found among AA, but not CA men and women, as indicated by both lower a wakening and higher bedtime cortisol levels [50]. Although the precise reasons for lower a wakening cortisol levels and flatter diurnal slopes are unclear, chronic persistent stressors and environmental disadvantages have been proposed [51, 52].

Many studies have linked both acute and chronic stresses to HPA axis dysregulation: repeated episodes of stress can induce acute phase responses (APR) and chronic inflammatory processes, as indicated by elevations in CRP: the end result is CVD, T2DM, MS, and/or obesity [45, 47, 53–59]. Initially the high levels or excess cortisol are associated with increased adiposity, and particularly in the visceral fat [47], but eventually, chronic stress may result in low cortisol levels due to adrenal exhaustion and/or heightened sensitivity to glucocorticoids (GC). This is an area where further research is needed.

4. Insulin Resistance and Glucocorticoid Sensitivity

Obesity is characterized by a spectrum of abnormal insulin secretion, insulin resistance (IR), and T2DM. One mechanism that may lead to the development of IR is heightened GC sensitivity [18]. GC, in particular cortisol, serves as a key physiologic modulator in maintaining energy balance and mobilization of energy substrate [60]. However, the magnitude of GC effects on IR and other metabolic actions is likely determined by the density and affinity of glucocorticoid receptors (GR) in various regions of the brain and peripheral tissues. GR may be under- or overexpressed, have altered binding affinities, interact with other ligands, and/or respond to other such factors, all of which may lead to a state of GC resistance or heightened GC sensitivity [59]. Importantly, Islam et al. [61] showed that obese CA and AA men and women have higher GR densities in leukocytes when compared to normal and overweight men and women and that GR density was strongly correlated with waist circumference. Increased GC action in liver and adipose tissue would likely enhance IR, impair glucose tolerance, and promote stress-induced obesity [61]. Moreover, administration of GC such as dexamethasone, and therapeutic treatment with GC, frequently impair glucose tolerance and promote IR, although the mechanism is not fully understood [61–64]. Also, persons who become glucose intolerant after treatment with GC are more likely to develop T2DM in the future [65, 66]. In addition to GC actions and GR sensitivity, abnormal regulation of the HPA axis alone contributes to IR [67, 68].

Several studies have demonstrated that insulin and glucose concentrations are higher in obese individuals compared to normal weight controls [69]. Relative to ethnic/racial groups, Palaniappan et al. [70] demonstrated that fasting insulin levels were significantly higher in AA compared to CA in both normal and overweight BMI categories. Also, AA women are more likely to be diagnosed with IR and T2DM compared to CA women [71, 72]. Hyperinsensitivity to GC may help explain the higher prevalence of IR in AA [18]. Following treatment with dexamethasone, AA maintained greater fasting IR, as determined by HOMA, and higher fasting insulin levels than CA [18]. Additionally, AA displayed a significantly higher postmeal IR than CA, as measured by insulin areas under the curve (AUC) and higher peak postprandial insulin levels under dexamethasone conditions [18]. Table 3 presents the means for fasting glucose and insulin, calculated, HOMAs and AUC for glucose and insulin following the meal [18]. Moreover, serum insulin 50
minutes after a standardized meal was significantly higher in AAs than CAs [37]. In addition to adults, studies on prepubertal children have shown that despite having similar BMI, BP%, and visceral adiposity, insulin sensitivity is 20% lower and insulin secretion is higher in Africans versus CAs [73]. Overall, this hyperinsulinemia, induced by stress or steroids, may reflect a prediabetic state, and having access to such information would be critical for preventing the continuation of the epidemic of obesity, IR, and T2DM in AA [18].

Of note, the TG/HDL-C ratio, which has been reported to be closely related to IR in CA individuals, is not diagnostic for IR in AAs or Africans [15, 38], Kim Dornier et al. [15] and others [12] have shown that although more AAs are likely to be IR, a significantly lower percentage of AA met the proposed cutoffs for the TG/HDL-C. Thus, predicting IR in AA from the TG/HDL-C is inappropriate unless different cutoff criteria are established. Additionally, although WC is an outstanding predictor of IR in CA, it is not as good a predictor as in AA [15]. Therefore, traditional measures of IR to identify AA at risk lack sensitivity and specificity; however, administration of GCs may be more effective in AA for uncovering predisposition for developing T2DM and possibly CVD than current measures. Clearly promoting early identification of risk and halting the prevalence of T2DM among AAs are critical, so consensus on the refinement of criteria and tools for assessment is needed.

Finally the role of psychosocial, socioeconomic, and environmental factors in the development of IR and obesity remains to be determined. Previous work has demonstrated a relationship between positive appraisal and lower HOMA-IR and the use of negative appraisal as a coping style with increased insulin AUC following a meal [24]. The impact of these factors is important but will not be discussed further here.

5. Physical Activity and Cardiovascular Fitness

Physical inactivity serves as a major role in the rising prevalence of obesity, although other factors such as excess energy intake also contribute [74]. In fact, lack of physical activity is a leading contributor to the rapid rise in obesity among AA and Hispanic populations, particularly among women [75], and is the fourth leading cause of death worldwide [76]. It is clear that a sedentary lifestyle contributes to CVD, hypertension, T2DM, obesity, MS, IR, and hyperlipidemia. Although the beneficial health effects of physical activity are common knowledge and widely recognized, most individuals do not achieve the recommended levels, and many report no leisure-time physical activity [77].

Unfortunately, AA women are less likely to be physically active than CA women, and AA women report less leisure-time activity, fewer hours spent standing and fewer flights of stairs climbed per day than CA women [78]. Resting energy expenditure and resting fat oxidation have also been shown to be depressed with obesity and may be lower in AA than in CA women, which could lead to a greater weight gain among AA than CA [46]. Interestingly, a study conducted by Lee and Arslanian showed significant difference in fat oxidation rates between African and CA girls, but not between African and CA boys in response to the multistage graded treadmill task [79]. Thus AA women may be at highest risk for reasons above and beyond their level of activity.

Aerobic fitness is important in the development of obesity, with a greater aerobic fitness being associated with a lower risk of obesity, MS, CVD, hypertension, and T2DM [13, 15, 20, 24, 80, 81]. AAs have a lower mean maximal aerobic exercise capacity compared to European Americans [82], and AA men have been reported to have a 7% lower exercise capacity than CA men [75]. Other cross-sectional studies have shown AA to have a lower VO2max than do CA, even after adjusting for body composition [49]. Importantly, aerobic fitness is significantly and negatively related to adiposity with a high initial fitness resulting in less adipose tissue gains over a period of time [49]. Also, a strong inverse association between aerobic fitness and body fat has been reported among AAs [83]. Because of the important relationship between fitness and CVD, Zeno et al. [20] examined VO2max, the primary index of cardiovascular fitness, in association with cardiovascular risk factors in healthy AA and CA: they found that 57% of AAs fell within the fair/low fitness group as compared to only 40% of CAs (Figure 1). Moreover, those with fair/low fitness were most likely to have multiple risk factors for CVD [20]. Finally, Gaillard et al. showed that moderate aerobic fitness is associated with reduced atherogenic lipid and lipoproteins profile in overweight or
Obese AA women, which could potentially lead to a lower risk of CVD [84]. Women in their very low and low aerobic fitness groups had higher glucose and insulin values, greater body weight, BMI, and %BF, and lower lean body mass when compared to the moderate fitness group [84]. Thus, it is clear that aerobic capacity or fitness is protective, and AA men and women could benefit substantially from regular exercise. Of note, many studies have also shown a strong inverse association between CRP and aerobic fitness [20, 80, 85, 86], which completes the circle: aerobic fitness, HPA axis function, and inflammation. Those who are regular exercisers and have moderate to high aerobic fitness will be less obese, have minimal systemic inflammatory processes, and have a properly functioning HPA axis. These should be the primary criteria for obesity and chronic disease risk.

Overall, educating sedentary patients to improve fitness levels by promoting regular, moderate, aerobic, or high-intensity activities will be critical for improving the health of all men and women, but in particular AA women. Although many studies are positive, the Diabetes Prevention Program Research Group demonstrated that modest aerobic exercise (brisk walking 30 min, 5 times a week) reduced the risk for developing T2DM by 58% [87]. Health care providers should inform and counsel patients to engage in regular physical activity with a goal of enhancing aerobic fitness and lowering obesity. Aerobic fitness and physical activity should always be assessed, as inactivity could be the primary criteria for early identification of those at risk for T2DM and CVD in nondiabetic, overweight, and obese populations—both in AA and CA populations.

6. Summary

The increasing prevalence of obesity has become a public health crisis in the United States. However, obesity disproportionately affects AA. Approximately 30% of CA adults are obese compared to 45% of AA adults [88]. Despite this trend, the most widely used treatments for overweight and obesity in U.S.A are largely ineffective [2]. The current paper focused on ethnic variations associated with MS indicators, regulation of the HPA axis, IR, GR, and physical activity—all of which are associated with obesity and chronic diseases. Ethnic-specific criteria should be established if MS is to be used as an early indicator, but factors such as aerobic fitness and CRP may be far more meaningful than conventional indicators when early intervention is the goal. The literature is clear in that a dysregulated HPA axis may lead to obesity and is a risk factor for CVD. Finally, regular physical activity is critical for overcoming obesity. AAs have lower aerobic capacity and are under greater psychosocial stress than CAs. Health care providers must assess levels of physical activity and aerobic fitness; they should encourage sedentary patients to increase physical activity regardless of their body weight and diabetic status.

Conflict of Interests

The authors have no conflict of interests to report.

Acknowledgments

This work was made possible by the US Army Medical Research and Materiel Command, Fort Detrick, Maryland, Peer-Reviewed Medical Research Program Award number DAMD17-03-2-0024. The opinions and assertions expressed herein are those of the authors and should not be construed as reflecting those of the Uniformed Services University of the Health Sciences (USUHS) or the Department of Defense.

References

[1] K. M. Flegal, M. D. Carroll, C. L. Ogden, and L. R. Curtin, "Prevalence and trends in obesity among US adults, 1999–2008," Journal of the American Medical Association, vol. 303, no. 3, pp. 235–241, 2010.
[2] T. A. Wadden, K. D. Brownell, and G. D. Foster, "Obesity: responding to the global epidemic," Journal of Consulting and Clinical Psychology, vol. 70, no. 3, pp. 510–525, 2002.
[3] G. E. Duncan, S. D. Anton, R. L. Newton Jr., and M. G. Perri, "Comparison of perceived health to physiological measures of health in black and white women," Preventive Medicine, vol. 36, no. 5, pp. 624–628, 2003.
[4] D. K. Wilson, H. G. Lawman, M. Segal, and S. Chappell, "Neighborhood and parental supports for physical activity in minority adolescents," American Journal of Preventive Medicine, vol. 41, no. 4, pp. 399–406, 2011.
[5] R. L. Weinsier, G. R. Hunter, P. A. Zuckerman et al., "Energy expenditure and free-living physical activity in black and white women: comparison before and after weight loss," The American Journal of Clinical Nutrition, vol. 71, no. 5, pp. 1138–1146, 2000.
[6] T. V. Barreira, A. E. Staiano, D. M. Harrington et al., "Anthropometric correlates of total body fat, abdominal adiposity,
and cardiovascular disease risk factors in a biracial sample of men and women,” Mayo Clinic Proceedings, vol. 87, no. 5, pp. 452–460, 2012.

[7] U. J. Ukegbu, D. C. Castillo, M. G. Knight et al., “Metabolic syndrome does not detect metabolic risk in African men living in the U.S.,” Diabetes Care, vol. 34, no. 10, pp. 2297–2299, 2011.

[8] K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmo-
nizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009.

[9] A. Rezaianzadeh, S. M. Namayandeh, and S. M. Sadr, “National cholesterol education program adult treatment panel III ver-
sus international diabetic federation definition of metabolic syndrome, which one is associated with diabetes mellitus and coronary artery disease?” International Journal of Preventive Medicine, vol. 3, no. 8, pp. 552–558, 2012.

[10] R. H. Eckel, S. M. Grundy, and P. Z. Zimet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005.

[11] S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005.

[12] A. E. Sumner and C. C. Cowie, “Ethnic differences in the ability of triglyceride levels to identify insulin resistance,” Atherosclerosis, vol. 196, no. 2, pp. 696–703, 2008.

[13] S. A. Zeno, P. A. Deuster, J. L. Davis, S. J. Kim-Dorner, A. T. Remaley, and M. Poth, “Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?” Metabolism, vol. 59, no. 2, pp. 299–304, 2010.

[14] S. X. Lin, M. Carnethon, M. Szklo, and A. Bertoni, “Racial/ ethnic differences in the association of triglycerides with other metabolic syndrome components: the multi-ethnic study of atherosclerosis,” Metabolic Syndrome and Related Disorders, vol. 9, no. 1, pp. 35–40, 2011.

[15] A. E. Sumner, J. Zhou, A. Doumaty et al., “Low HDL-cholesterol with normal triglyceride levels is the most common lipid pattern in West Africans and African Americans with metabolic syndrome: implications for cardiovascular disease prevention,” CVD Prevention and Control, vol. 5, no. 3, pp. 75–80, 2010.

[16] B. Frazier, C. W. Hsiao, P. Deuster, and M. Poth, “African American and Caucasian Americans: differences in glucocorticoid-induced insulin resistance,” Hormone and Metabolic Research, vol. 42, no. 12, pp. 887–891, 2010.

[17] L. Razouk and P. Munter, “Ethnic, gender, and age-related differences in patients with the metabolic syndrome,” Current Hypertension Reports, vol. 11, no. 2, pp. 127–132, 2009.

[18] S. A. Zeno, S. J. Kim-Dorner, P. A. Deuster, J. L. Davis, A. T. Remaley, and M. Poth, “Cardiovascular fitness and risk factors of healthy African Americans and Caucasians,” Journal of the National Medical Association, vol. 102, no. 1, pp. 28–35, 2010.

[19] M. Feinstein, H. Ning, J. Kang, A. Bertoni, M. Carnethon, and D. M. Lloyd-Jones, “Racial differences in risks for first cardiovascular events and noncardiovascular death: the atherosclerosis risk in communities study, the cardiovascular health study, and the multi-ethnic study of atherosclerosis,” Circulation, vol. 126, no. 1, pp. 50–59, 2012.

[20] E. S. Ford, C. Li, and G. Zhao, “Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the U.S.,” Journal of Diabetes, vol. 2, no. 3, pp. 180–193, 2010.

[21] Y. Wang and Q. J. Wang, “The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem,” Archives of Internal Medicine, vol. 164, no. 19, pp. 2126–2134, 2004.

[22] S. J. Kim-Dorner, C. O. Simpson-McKenzie, M. Poth, and P. A. Deuster, “Psychological and physiological correlates of insulin resistance at fasting and in response to a meal in African Americans and whites,” Ethnicity & Disease, vol. 19, no. 2, pp. 104–110, 2009.

[23] S. S. Yu, D. C. Castillo, A. B. Courville, and A. E. Sumner, “The triglyceride paradox in people of African descent,” Metabolic Syndrome and Related Disorders, vol. 10, no. 2, pp. 77–82, 2012.

[24] M. J. Barber, L. M. Mangravite, C. L. Hyde et al., “Genome-wide association of lipid-lowering response to statins in combined study populations,” PLoS ONE, vol. 5, no. 3, Article ID e9763, 2010.

[25] S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary,” Cardiology in Review, vol. 13, no. 6, pp. 322–327, 2005.

[26] S. Yusuf, S. Hawken, S. Ounpuu et al., “Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study,” The Lancet, vol. 366, no. 9497, pp. 1640–1649, 2005.

[27] J. F. Carroll, A. L. Chiapa, M. Rodriguez et al., “Visceral fat, waist circumference, and BMI: impact of race/ethnicity,” Obesity, vol. 16, no. 3, pp. 600–607, 2008.

[28] P. T. Katzmarzyk, G. A. Bray, F. L. Greenway et al., “Ethnic-specific BMI and waist circumference thresholds,” Obesity, vol. 19, no. 6, pp. 1272–1278, 2011.

[29] P. Deurenberg and M. Deurenberg-Yap, “Differences in body-composition assumptions across ethnic groups: practical con-
sequences,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 4, no. 5, pp. 377–383, 2001.

[30] A. E. Sumner, L. K. Micklefield, M. Ricks et al., “Waist circum-
ference, BMI, and visceral adipose tissue in white women and women of African descent,” Obesity, vol. 19, no. 3, pp. 671–674, 2011.

[31] S. Agarwal, D. R. Jacobs Jr., D. Vaidya et al., “Metabolic syn-
drome derived from principal component analysis and incident cardiovascular events: the multi ethnic study of atherosclerosis (MESA) and health, aging, and body composition (Health ABC),” Cardiology Research and Practice, vol. 2012, Article ID 919425, 9 pages, 2012.

[32] D. Martins, N. Tareen, G. Ogedegbe, D. Pan, and K. Norris, “The relative risk of cardiovascular death among racial and ethnic minorities with metabolic syndrome: data from the NHANES-II mortality follow-up,” Journal of the National Medical Association, vol. 100, no. 5, pp. 565–571, 2008.

[33] A. E. Staiano, B. A. Reeder, S. Elliott et al., “Body mass index versus waist circumference as predictors of mortality in Canadian adults,” International Journal of Obesity, vol. 36, no. 11, pp. 1450–1454, 2005.
W. Shen, M. Punyanitya, J. Chen et al., “Waist circumference correlates with metabolic syndrome indicators better than percentage fat,” Obesity, vol. 14, no. 4, pp. 727–736, 2006.

P. A. Deuster, S. J. Kim-Dorner, A. T. Remaley, and M. Poth, “Allostatic load and health status of African Americans and whites,” American Journal of Health Behavior, vol. 35, no. 6, pp. 641–653, 2011.

C. Giannini, N. Santoro, S. Caprio et al., “The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds,” Diabetes Care, vol. 34, no. 8, pp. 1869–1874, 2011.

S. Arslanian, “Insulin secretion and sensitivity in healthy African-American vs American white children,” Clinical Pediatrics, vol. 37, no. 2, pp. 81–88, 1998.

E. Ravussin and S. R. Smith, “Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus,” Annals of the New York Academy of Sciences, vol. 967, pp. 363–378, 2002.

M. D. DeBoer, M. J. Gurka, and A. E. Sumner, “Diagnosis of the metabolic syndrome is associated with disproportionately high levels of high-sensitivity C-reactive protein in non-hispanic black adolescents: an analysis of NHANES 1999–2008,” Diabetes Care, vol. 34, no. 3, pp. 734–740, 2011.

A. Kelley-Hedgepeth, D. M. Lloyd-Jones, A. Colvin et al., “Ethnic differences in C-reactive protein concentrations,” Clinical Chemistry, vol. 54, no. 6, pp. 1027–1037, 2008.

G. P. Chrousos and P. W. Gold, “The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis,” Journal of the American Medical Association, vol. 267, no. 9, pp. 1244–1252, 1992.

J. P. Herman and W. E. Cullinan, “Neurocircuity of stress: central control of the hypothalamo-pituitary-adrenocortical axis,” Trends in Neurosciences, vol. 20, no. 2, pp. 78–84, 1997.

B. M. Kudielka and S. Wüst, “Human models in acute and chronic stress: assessing determinants of individual hypothalamic-pituitary-adrenal axis activity and reactivity,” Stress, vol. 13, no. 1, pp. 1–14, 2010.

R. C. Hickner, J. Privette, K. McIver, and H. Barakat, “Fatty acid oxidation in African-American and Caucasian women during physical activity,” Journal of Applied Physiology, vol. 90, no. 6, pp. 2319–2324, 2001.

R. Pasquali, “The hypothalamic-pituitary-adrenal axis and sex hormones in chronic stress and obesity: pathophysiological and clinical aspects,” Annals of the New York Academy of Sciences, vol. 1264, no. 1, pp. 20–35, 2012.

P. Björntorp and R. Rosmond, “Obesity and cortisol,” Nutrition, vol. 16, no. 10, pp. 924–936, 2000.

M. S. Johnson, R. Figueroa-Colon, S. L. Herd et al., “Aerobic fitness, not energy expenditure, influences subsequent increase in adiposity in black and white children,” Pediatrics, vol. 106, no. 4, p. e50, 2000.

S. Cohen, J. E. Schwartz, E. Epel, C. Kirschbaum, S. Sidney, and T. Seeman, “Socioeconomic status, race, and diurnal cortisol decline in the Coronary Artery Risk Development in Young Adults (CARDIA) study,” Psychosomatic Medicine, vol. 68, no. 1, pp. 41–50, 2006.

R. A. Karb, M. R. Elliott, J. B. Dowd, and J. D. Morenoff, “Neighborhood-level stressors, social support, and diurnal patterns of cortisol: the Chicago community adult health study,” Social Science & Medicine, vol. 75, no. 6, pp. 1038–1047, 1982.

A. S. DeSantis, E. K. Adam, L. D. Doane, S. Mineka, R. E. Zinbarg, and M. G. Craske, “Racial/ethnic differences in cortisol diurnal rhythms in a community sample of adolescents,” Journal of Adolescent Health, vol. 41, no. 1, pp. 3–13, 2007.

P. H. Black, “The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X,” Brain, Behavior, and Immunity, vol. 17, no. 5, pp. 350–364, 2003.

M. S. Kopp and J. Rethelyi, “Where psychology meets physiology: chronic stress and premature mortality—the Central-Eastern European health paradox,” Brain Research Bulletin, vol. 62, no. 5, pp. 351–367, 2004.

R. Rosmond, “Role of stress in the pathogenesis of the metabolic syndrome,” Psychoneuroendocrinology, vol. 30, no. 1, pp. 1–10, 2005.

M. F. Dallman, N. C. Pecoraro, S. E. La Fleur et al., “Glucocorticoids, chronic stress, and obesity,” Progress in Brain Research, vol. 153, pp. 75–105, 2006.

E. A. Lucassen and G. Cizza, “The hypothalamic-pituitary-adrenal axis, obesity, and chronic stress exposure: sleep and the HPA axis in obesity,” Current Obesity Reports, vol. 1, no. 4, pp. 208–215, 2012.

G. E. Miller, E. Chen, and E. S. Zhou, “If it goes up, must it come down? chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans,” Psychological Bulletin, vol. 133, no. 1, pp. 25–45, 2007.

M. N. Silverman and E. M. Sternberg, “Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction,” Annals of the New York Academy of Sciences, vol. 1261, pp. 55–63, 2012.

A. A. Syed and J. U. Weaver, “Glucocorticoid sensitivity: the hypothalamic-pituitary-adrenal-tissue axis,” Obesity Research, vol. 13, no. 7, pp. 1131–1133, 2005.

A. Islam, Y. Chen, M. Poth, Z. P. Smith, and P. A. Deuster, “Glucocorticoid receptor density correlates with health risk factors and insulin resistance in Caucasian and African American subjects,” Experimental and Clinical Endocrinology & Diabetes, vol. 120, no. 8, pp. 477–481, 2012.

C. Binnert, S. Ruchat, N. Nicod, and L. Tappy, “Dexamethasone-induced insulin resistance shows no gender difference in healthy humans,” Diabetes & Metabolism, vol. 30, no. 4, pp. 321–326, 2004.

N. Nicod, V. Giusti, C. Besse, and L. Tappy, “Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers,” Obesity Research, vol. 11, no. 5, pp. 625–631, 2003.

D. H. van Raalte, K. A. Kwa, R. E. van Genugten et al., “Inslet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?” Metabolism: Clinical and Experimental. In press.

S. S. Fajans and J. W. Conn, “An approach to the prediction of diabetes mellitus by modification of the glucose tolerance test with cortisone,” Diabetes, vol. 3, no. 4, pp. 296–302, 1954.

J. E. Henriksen, F. Alford, G. M. Ward, and H. Beck-Nielsen, “Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients,” Diabetologia, vol. 40, no. 12, pp. 1439–1448, 1997.

P. Björntorp, G. Holm, and R. Rosmond, “Thyroidal cortisol in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration,” The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 11, pp. 4093–4098, 2000.
[69] R. Pasquali, L. Gagliardi, V. Vicennati et al., “ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome,” *International Journal of Obesity and Related Metabolic Disorders*, vol. 23, no. 4, pp. 419–424, 1999.

[70] L. P. Palaniappan, M. R. Carnethon, and S. P. Fortmann, “Heterogeneity in the relationship between ethnicity, BMI, and fasting insulin,” *Diabetes Care*, vol. 25, no. 8, pp. 1351–1357, 2002.

[71] A. C. Ellis, J. A. Alvarez, W. M. Granger, F. Ovalle, and B. A. Gower, “Ethnic differences in glucose disposal, hepatic insulin sensitivity, and endogenous glucose production among African American and European American women,” *Metabolism*, vol. 61, no. 5, pp. 634–640, 2012.

[72] C. J. Tsai and E. L. Giovannucci, “Hyperinsulinemia, insulin resistance, vitamin D, and colorectal cancer among whites and African Americans,” *Digestive Diseases and Sciences*, vol. 57, no. 10, pp. 2497–2503, 2012.

[73] S. A. Arslanian, R. Saad, V. Lewy, K. Danadian, and J. Janosky, “Hyperinsulinemia in African-American children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity,” *Diabetes*, vol. 51, no. 10, pp. 3014–3019, 2002.

[74] J. White and R. Jago, “Prospective associations between physical activity and obesity among adolescent girls: racial differences and implications for prevention,” *Archives of Pediatrics & Adolescent Medicine*, vol. 166, no. 6, pp. 522–527, 2012.

[75] J. C. Lovejoy, C. M. Champagne, S. R. Smith, L. de Jonge, and H. Xie, “Ethnic differences in dietary intakes, physical activity, and energy expenditure in middle-aged, premenopausal women: the healthy transitions study,” *American Journal of Clinical Nutrition*, vol. 74, no. 1, pp. 90–95, 2001.

[76] S. Lee and S. A. Arslanian, “Fat oxidation in black and white youth: a metabolic phenotype potentially predisposing black girls to obesity,” *Journal of Clinical Endocrinology and Metabolism*, vol. 93, no. 11, pp. 4547–4551, 2008.

[77] R. V. Brown, B. G. Kral, L. R. Yanek et al., “Ethnic-specific determinants of exercise capacity in a healthy high-risk population,” *Medicine and Science in Sports and Exercise*, vol. 44, no. 6, pp. 1150–1156, 2012.